Cost analysis of rapid diagnostics for drug-resistant tuberculosis
Citation: Groessl, E.J., Ganiats, T.G., Hillery, N. et al. Cost analysis of rapid diagnostics for drug-resistant tuberculosis. BMC Infect Dis 18, 102 (2018). https://doi.org/10.1186/s12879-018-3013-0
Abstract: Growth-based drug susceptibility testing (DST) is the reference standard for diagnosing drug-resistant tuberculosis (TB), but standard time to result (TTR) is typically ≥ 3 weeks. Rapid tests can reduce that TTR to days or hours, but accuracy may be lowered.
In addition to the TTR and test accuracy, the cost of a diagnostic test may affect whether it is adopted in clinical settings. We examine the cost-effectiveness of rapid diagnostics for extremely drug-resistant TB (XDR-TB) in three different high-prevalence settings.
In addition to the TTR and test accuracy, the cost of a diagnostic test may affect whether it is adopted in clinical settings. We examine the cost-effectiveness of rapid diagnostics for extremely drug-resistant TB (XDR-TB) in three different high-prevalence settings.
Author(s): BMC Infectious Diseases
Year: 2018
Language: English
Resource Type: Journal Articles
Source: Other
Filed under: Cost, Diagnostics, DR-TB, Drug-resistant TB, Journal Article, Research, Testing, XDR-TB
